- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02873000
Incentive Spirometry in Non-critically Ill Hospitalized Patients With Acute Respiratory Failure
A Prospective Randomized Trial of Incentive Spirometry in Non-critically Ill Hospitalized Patients With Shortness of Breath
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In recent years the focus in medicine has shifted towards efficient utilization of resources and improving patient outcomes. Incentive spirometry (IS) is a tool that mimics the natural process of yawning or sighing by allowing the user to take deep breaths in a controlled setting. This is a lung inflating maneuver that has been suggested to decrease the rate of pulmonary complications. The focus of utilization of IS and current studies has been predominantly on the post-operative surgical patient population. The mechanism of pulmonary complications in surgical patients is mixed in etiology possibly related to anesthesia, analgesics, pain and immobility leading to shallow breathing and subsequent atelectasis with concurrent hypoxia and risk of infection. The use of lung expanding maneuvers such as that provided by IS are thought to counteract shallow breathing thereby improving pulmonary outcomes. However, contrary to physiological theory, multiple studies and meta-analysis have failed to demonstrate its efficacy. The results of these studies are in direct conflict with what is expected scientifically.
The authors of this paper set out to find the reason for discordant data in existing literature, and found that there have been multiple methodological limitations associated with existing studies; hence, interpretation and recommendations based on current data should be done with caution. The common denominator in repeated criticisms of existing studies is lack of reporting on patient compliance with IS after it is prescribed. This is a major confounder, in clinical experience IS is often observed sitting dormant at patients' bedside. These observations are in synchrony with criticisms reported in literature and raise serious questions about validity of existing data that should be acknowledged. Despite lack of convincing evidence, IS is routinely prescribed by physicians in hospital medicine. IS is a low cost tool, nevertheless, the increasing frequency of its use is accumulating to a larger proportion of health care costs. This calls for further evaluation with a study of higher methodological quality to address the limitations of prior studies.
The scope of this study is different than that of existing studies in that it will evaluate the utility of IS in general medical patients. The sub-set of patients that are the focus of this study are those admitted with the chief complaint of "shortness of breath." The disease process in the former group leading to shortness of breath includes fluid over-load such as that in congestive heart failure, or an underlying lung process such as pneumonia, COPD, and/or pulmonary embolism. There is a parallel between mechanism of hypoxia in these patients and surgical patients in that these patients too often have pain and take high doses of analgesics, have shallow monotonous breathing and are immobile for long periods of time. From a physiological standpoint sustained maximal inhalation maneuvers may reverse and prevent progression of atelectasis by maintaining airway patency in all patients with shallow breathing of varying etiology not just the surgical sub-set.
In a tertiary center community teaching hospital the effectiveness of IS in general medical wards will be evaluated using a single center randomized clinical trial. The goal is to offer a study that overcomes the limitations of prior studies. Lack of strong evidence based data has led to inconsistencies in practice of physicians leading to higher health care costs. The authors hope to design a study of high methodological quality to assess the effectiveness of IS in medical patients; thereby closing the knowledge gap in evidence based practices that may aid physicians in their decision to utilize IS.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Imran Naqvi, MD
- Phone Number: (513) 686-5446
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45236
- Jewish Hospital of Cincinnati
-
Contact:
- Imran Naqvi, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion:
- Patients presenting to the ED with chief complaint of "shortness of breath," admitted to the hospitalist service
- Age >65 yrs of age
Exclusion:
- Patients who can not follow instructions/use IS device
- Cognitive impairment (Dementia/delirium/Developmental delay)
- Heavy sedation
- Inability to take part in deep breathing due to pain or diaphragmatic dysfunction
- Suicide or psych watch
- Patients under isolation
- ICU admission or care within the last 48 hours
- Recent hospitalization 30 days.
- Intubation within the last 60 days
- Routine care group patients that have IS prescribed to them by the admitting MD
- Chronic/Home oxygen dependence
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Routine Care Group
Routine Care (R): Standard of care therapy based on admitting diagnosis
|
|
Experimental: Experimental Group
Intervention 1 (E1): addition of incentive spirometry every hour while awake; There will be a computerized protocol with specific instructions documenting:
|
Incentive Spirometer is a tool that allows for deep breathing in a controlled setting while providing the user with visual feedback demonstrating the inspiratory volume of each breath.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Forced Vital Capacity (FVC)
Time Frame: From admission to the hospital up to 48 hours
|
FVC will be measured on admission and at 48 hours
|
From admission to the hospital up to 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective perception of respiratory distress
Time Frame: From admission to the hospital up to 48 hours
|
Visual analogue scale (score 0-5) will be used to measure patient's subjective perception of respiratory distress on the day of admission, at 24 hours and at 48 hours.
|
From admission to the hospital up to 48 hours
|
Length of Stay (LOS)
Time Frame: Starting on admission and until discharge from the hospital (up to 14 days)
|
Actual length of stay measured in days from date of admission to discharge will be reported per subject per group.
|
Starting on admission and until discharge from the hospital (up to 14 days)
|
Pulmonary complications
Time Frame: Starting on admission and continuing for 7 days
|
The total number of complications will be reported for each subject: i) radiographically as defined by the radiologist as new or worsening: atelectasis/consolidation; ii) clinical assessment defined by worsening or new respiratory symptoms (shortness of breath, cough and dyspnea on exertion) and physical examination findings (wheezing, rhonchi, rales, crackles) iii) New BiPAP requirement or emergent intubation.
|
Starting on admission and continuing for 7 days
|
Change in oxygen requirement
Time Frame: Starting on admission and continuing for 72 hours
|
Measure percentage change in oxygen requirement in each subject in both groups.
|
Starting on admission and continuing for 72 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Imran Naqvi, MD, Jewish Hospital of Cincinnati
- Principal Investigator: Nasim Motayar, MD, Jewish Hospital of Cincinnati
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Department of Health and Human ServicesNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Methodist Health SystemCompletedHospital-acquired Pneumonia | Ventilator-associated PneumoniaUnited States
Clinical Trials on Incentive Spirometry
-
Taipei Medical University Shuang Ho HospitalNot yet recruitingSleep Apnea, Obstructive | Bariatric Surgery Candidate
-
Riphah International UniversityCompletedHiatal Hernia | Cholecystitis | Choledocholithiasis | Splenomegaly | Diaphragmatic Hernia | Perforated Duodenal Ulcer | Malignant Pancreatic Neoplasm | Benign Pancreas Tumor | Splenic InfarctionPakistan
-
Menoufia UniversityCompleted
-
McMaster UniversityMcMaster Surgical AssociatesCompletedLung Neoplasms | Benign Lung DiseaseCanada
-
Cliniques universitaires Saint-Luc- Université...Completed
-
Chaudhry Pervaiz Elahi Institute of CardiologyRecruitingPulmonary ComplicationsPakistan
-
Universidade Federal de PernambucoConselho Nacional de Desenvolvimento Científico e TecnológicoUnknown
-
Milton S. Hershey Medical CenterTerminatedPostoperative Respiratory ComplicationUnited States
-
Dr Cipto Mangunkusumo General HospitalCompletedMajor Abdominal Surgery | Postoperative Pulmonary Complication | Incentive Spirometry
-
University of North Carolina, Chapel HillCompleted